April 3, 2020—BD and BioGX announced that the FDA has granted emergency use authorization for a diagnostic test that will enable hospitals to screen for COVID-19 on site and get results in less than three hours.
The test runs on the BD Max System, which can process 24 samples simultaneously. BD is working on an antigen test for its point-of-care BD Veritor System.